Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
A paper in Alzheimer's & Dementia highlights SpeechDx's role in developing AI tools that use speech patterns to detect early cognitive decline and support personalized Alzheimer's care.
AnHorn Medicines announced that its neuroprotective candidate AH-008 has received U.S. FDA IND clearance and Taiwan CDE Index Case designation, enabling the company to begin clinical trials for preventing chemotherapy-induced peripheral neuropathy.
Co-Diagnostics hosted a delegation from its Saudi joint venture CoMira Diagnostics in Salt Lake City for the unveiling of a future automated PCR test kit manufacturing line, part of a planned technology transfer to Saudi Arabia.
Boltz has announced a collaboration with Takeda to provide its biomolecular AI models and platform across Takeda's research organization, supporting structure prediction, affinity estimation, and molecular design.
XEOS announced the publication of the multicenter BrIMA study in JAMA Surgery, showing that its AURA 10 specimen PET-CT system significantly improved intraoperative margin assessment in breast-conserving surgery.
Arbital Health has introduced ATLAS, a new actuarial modeling tool to help Accountable Care Organizations evaluate provider networks and financial performance under the Centers for Medicare & Medicaid Services' new LEAD Model.
Channel Robotics has raised $4.6 million, including a $2.5 million Seed+ round led by True Ventures, to develop its handheld AI-enabled endoscopic robotic platform and prepare for FDA submission in 2027.
Workera announced that a global medical device manufacturer achieved a 42% average proficiency gain in 13 days using its skills data platform, reaching best-in-class learning velocity and uncovering hidden workforce capabilities.
Vali Health has emerged from stealth with $6 million in funding to develop responsible AI infrastructure for home care agencies, aiming to automate workforce coordination and improve continuity of care.
Lunai Bioworks has secured its first revenue-generating defense contract with the U.S. government through BioSymetrics, formed a national research consortium, and initiated legal proceedings over alleged market manipulation.
LG AI Research has signed a master agreement with D&D Pharmatech to jointly develop oral peptide therapeutics using artificial intelligence, aiming to accelerate drug discovery and improve treatment safety and absorption.
Icarus Medical, based in Charlottesville, Virginia, has closed a $7.2 million Series A funding round to accelerate commercialization and development of its orthopedic bracing technology.
HistoIndex's AI-based quantitative analysis confirmed significant liver fibrosis improvement in D&D Pharmatech's Phase 2 trial of zabopegdutide for MASH, reinforcing earlier histopathological findings.
Coreline Soft and Mint Medical have announced a partnership to integrate Coreline's AVIEW AI imaging platform into Mint Medical's mint Lesion system to support structured lung cancer screening workflows in Germany and beyond.
CCRM and its subsidiary OmniaBio have partnered with Avectas to evaluate an automated cell therapy manufacturing platform aimed at improving scalability and efficiency across a global network of advanced therapy hubs.
DeepIntent has introduced Helix AI, an agentic AI platform designed for healthcare marketers to analyze and activate audiences using natural language across multiple channels.
Toboggan Labs has joined Mila’s Industry Partner Network to strengthen its healthcare AI capabilities, gaining access to research collaboration and knowledge sharing opportunities.
Harbour BioMed and BioMap have formed a strategic partnership to create MegaStream TechBio, an AI based drug development platform focused on complex biologics across multiple therapeutic areas.
IDBS and Alchemi have announced a partnership to connect Alchemi’s AI agents with the IDBS Polar platform, enabling faster and compliant drafting of regulatory filings in the biopharma sector.
cliexa and OpiSafe have announced a partnership to deliver an AI powered platform that combines opioid use disorder risk prediction, tapering management, and behavioral health referral tools for healthcare organizations.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
